<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373019</url>
  </required_header>
  <id_info>
    <org_study_id>CC-RD1</org_study_id>
    <nct_id>NCT03373019</nct_id>
  </id_info>
  <brief_title>Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
  <official_title>A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to evaluate therapeutic efficacy of Chidamide combined&#xD;
      with R-GDP （rituximab/gemcitabine/dexamethasone/cisplatin）in treating Patients with relapsed&#xD;
      or refractory Diffuse Large B-cell Lymphoma (DLBCL) not suitable for transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment outcome of patients with relapsed or refractory Diffuse Large B-cell Lymphoma&#xD;
      (DLBCL) are not satisfactory especially for those not suitable for transplantation. One of&#xD;
      main reason is chemotherapy resistance. The investigators conducted this study to evaluate&#xD;
      the efficacy of Chidamide combined with R-GDP(rituximab/gemcitabine/dexamethasone/cisplatin)&#xD;
      in treating patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) not&#xD;
      suitable for transplantation. Chidamide is a novel benzamide type of subtype-selective&#xD;
      histone deacetylase (HDAC) inhibitor. It has been approved by China Food and Drug&#xD;
      Administration (CFDA) for treatment of relapsed or refractory peripheral T-cell lymphoma&#xD;
      (PTCL) in Chinese population. The investigators' pre-clinical data suggested that this agent&#xD;
      might be also efficient in the treatment of relapsed/refractory B cell lymphoma. In this&#xD;
      open-label, non-randomized, phase II study, the investigators aimed to observe the efficacy&#xD;
      and safety of chidamide combined with R-GDP in patients with relapsed or refractory Diffuse&#xD;
      Large B-cell Lymphoma (DLBCL) not suitable for transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">December 21, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>6 weeks</time_frame>
    <description>overall response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR</measure>
    <time_frame>6 weeks</time_frame>
    <description>complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 year PFS</measure>
    <time_frame>3 years</time_frame>
    <description>3 year progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>throughout the treatment period，up to 6 months</time_frame>
    <description>adverse event related to treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Chidamide</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Neoplasm by Histology</condition>
  <condition>Neoplasms</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <condition>Lymphatic Diseases</condition>
  <condition>Immunoproliferative Disorders</condition>
  <condition>Immune System Diseases</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Cyclophosphamide</condition>
  <condition>Rituximab</condition>
  <condition>Gemcitabine</condition>
  <condition>Cisplatin</condition>
  <condition>Dexamethasone</condition>
  <condition>HDAC Inhibitor</condition>
  <arm_group>
    <arm_group_label>Chidamide combined with R-GDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide combined with R-GDP</intervention_name>
    <description>Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off</description>
    <arm_group_label>Chidamide combined with R-GDP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages: 18-75 years old&#xD;
&#xD;
          2. Relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) previous treated with&#xD;
             standard chemoimmunotherapy&#xD;
&#xD;
          3. Not willing or not suitable for hematopoietic stem cell transplantation (HSCT)&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) index &lt; 2&#xD;
&#xD;
          5. Informed consent available&#xD;
&#xD;
          6. Life expectancy of more than 3 months;&#xD;
&#xD;
          7. Ultrasonic cardiogram showed left ventricle ejection fraction ≥ 50%, EKG showed on&#xD;
             signs of myocardial ischemia, with no previous arrhythmia which need pharmacological&#xD;
             intervention.&#xD;
&#xD;
          8. Bone marrow function: ANC ≥ 1.5 × 109/L, PLT ≥ 100 × 109/L, Hb ≥ 80g/L;&#xD;
&#xD;
          9. Liver function: total bilirubin, ALT and AST were &lt;1.5 × UNL (the upper limit of&#xD;
             normal value)&#xD;
&#xD;
         10. Renal function: Cr&lt;1.5 × UNL and creatinine clearance &gt; 50ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of treatment of HDAC inhibitor.&#xD;
&#xD;
          2. Plan of HSCT in the future&#xD;
&#xD;
          3. Significant pericardial effusion showed by chest CT scan&#xD;
&#xD;
          4. Prior history of other cancers except treated cervical or basal cell skin carcinoma,&#xD;
             organ transplantation&#xD;
&#xD;
          5. Syphilis or human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          6. Pregnant or lactating women&#xD;
&#xD;
          7. History of organ transplantation&#xD;
&#xD;
          8. Serious active infections (including hepatitis)&#xD;
&#xD;
          9. Serious neurological or psychiatric history, including dementia or epilepsy.&#xD;
&#xD;
        Termination criteria:&#xD;
&#xD;
          1. Withdrew consent&#xD;
&#xD;
          2. Researchers think it is necessary to terminate the study;&#xD;
&#xD;
          3. Disease progression or death;&#xD;
&#xD;
          4. Poor compliance&#xD;
&#xD;
          5. Subclinical or clinical cardiac toxicity;&#xD;
&#xD;
          6. Unable to continue treatment because of severe toxicity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kai Xue, MD</last_name>
    <phone>13818659448</phone>
    <email>xuekaishanghai@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kai Xue</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Xue, MD</last_name>
      <phone>13818659448</phone>
      <email>xuekaishanghai@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kai Xue</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Xue, MD</last_name>
      <phone>13818659448</phone>
      <email>xuekaishanghai@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Junning Cao, MD</last_name>
      <phone>13818659448</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kai Xue, MD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>chidamide</keyword>
  <keyword>R-GDP</keyword>
  <keyword>diffuse large B-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Lymphatic Diseases</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Immunoproliferative Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

